The biological role and therapeutic biomarker potential of PPP2R4 in lung cancer: a pre-clinical proof-of-concept study in human and mouse NSCLC models

Lung cancer is one of the most frequently occurring and deadly cancers in Belgium. Despite the relative success of molecularly targeted therapeutics in a small subgroup of lung cancer patients, for the large majority of patients, efficient treatment options are currently lacking. In this project, we will investigate if and how a frequently occurring molecular alteration in a tumor suppressor gene (PPP2R4) can influence the efficiency of existing and experimental therapeutics. To this end, we make use of human lung cancer cell lines, a mouse model of lung cancer, and human lung tumor tissue. By taking the specific PPP2R4 status of the tumor into account, we hope to be able to offer lung cancer patients more efficient, personalized therapies.